Viewing Study NCT04365933


Ignite Creation Date: 2025-12-25 @ 2:56 AM
Ignite Modification Date: 2025-12-26 @ 1:36 AM
Study NCT ID: NCT04365933
Status: COMPLETED
Last Update Posted: 2022-08-25
First Post: 2020-04-23
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
Sponsor: Enyo Pharma
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module